Skip to content

Personalized functional connectivity guided rTMS treatment for adolescent patients with major depressive disorder

Personalized functional connectivity guided rTMS treatment for adolescent patients with major depressive disorder

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057637
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MDD

Interventions

Group 1 :pgACC FC-guided iTBS

Sponsors

The Affiliated Hospital of Hangzhou Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for depression in the International Classification of Diseases DSM-V, and be diagnosed with depression; 2. HAMD-17 > 18 points (Melzeretal.,2012); Mood Disorder Questionnaire < 7 points; 3. The current depressive episode was confirmed by the questionnaire of Emotional Disorders and schizophrenia in school-age children, KidDI-SADS Lifetime Edition (K-SADS-PL); 4. No gender limitation, age 12-18 years, right-handed, ethnic Han; 5. Subjects who are able to understand and willing to strictly follow the clinical trial protocol to complete the study, have informed consent from the guardian and can sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Contraindicated patients with MRI and TMS; 2. Severe heart, liver and kidney diseases, no thyroid, tumor, blood history, rheumatism, malnutrition and nervous system diseases; 3. Patients previously treated with rTMS or ECT; 4. Schizophrenia, bipolar disorder, history of abuse of tobacco, alcohol and other psychoactive substances; 5. People at high risk of suicide; 6. The patient is a pregnant or lactating woman or planning to become pregnant; 7. No immunomodulators and hormone preparations for at least half a year, no antipyretic and analgesic drugs for 2 weeks; 8. Those considered unsuitable for inclusion by researchers.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale, HAMD;

Secondary

MeasureTime frame
Hamilton Anxiety Scale, HAMA;Snaith-Hamilton Pleasure Scale, SHAPS;Digital symbol substitution test, DSST;Digital span test, DST;Theamplitudeof low-frequency fluctuations, ALFF;Functional connection, FC;

Countries

China

Contacts

Public ContactZang Yufeng

Hangzhou Normal University

zangyf@hznu.edu.cn+86 18606517380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026